Structure Therapeutics American Depositary Shares logo

Structure Therapeutics American Depositary SharesNASDAQ: GPCR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 February 2023

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.87 B
-45%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-88%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:27:39 GMT
$32.71-$1.19(-3.51%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

GPCR Latest News

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
benzinga.com19 November 2024 Sentiment: POSITIVE

A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
globenewswire.com15 November 2024 Sentiment: POSITIVE

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
globenewswire.com05 November 2024 Sentiment: POSITIVE

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).

Structure Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com26 August 2024 Sentiment: POSITIVE

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
zacks.com24 July 2024 Sentiment: POSITIVE

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

The 3 Most Undervalued Biotech Stocks to Buy in July 2024
investorplace.com12 July 2024 Sentiment: POSITIVE

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.

Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
zacks.com11 June 2024 Sentiment: POSITIVE

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
fool.com11 June 2024 Sentiment: POSITIVE

Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Wegovy and experimental weight management treatments.

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
fool.com09 June 2024 Sentiment: POSITIVE

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
globenewswire.com07 June 2024 Sentiment: POSITIVE

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 additional ADSs,  at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics.

  • 1(current)

What type of business is Structure Therapeutics American Depositary Shares?

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

What sector is Structure Therapeutics American Depositary Shares in?

Structure Therapeutics American Depositary Shares is in the Healthcare sector

What industry is Structure Therapeutics American Depositary Shares in?

Structure Therapeutics American Depositary Shares is in the Biotechnology industry

What country is Structure Therapeutics American Depositary Shares from?

Structure Therapeutics American Depositary Shares is headquartered in United States

When did Structure Therapeutics American Depositary Shares go public?

Structure Therapeutics American Depositary Shares initial public offering (IPO) was on 03 February 2023

What is Structure Therapeutics American Depositary Shares website?

https://structuretx.com

Is Structure Therapeutics American Depositary Shares in the S&P 500?

No, Structure Therapeutics American Depositary Shares is not included in the S&P 500 index

Is Structure Therapeutics American Depositary Shares in the NASDAQ 100?

No, Structure Therapeutics American Depositary Shares is not included in the NASDAQ 100 index

Is Structure Therapeutics American Depositary Shares in the Dow Jones?

No, Structure Therapeutics American Depositary Shares is not included in the Dow Jones index

When was Structure Therapeutics American Depositary Shares the previous earnings report?

No data

When does Structure Therapeutics American Depositary Shares earnings report?

The next expected earnings date for Structure Therapeutics American Depositary Shares is 07 March 2025